Disease landscape

Leukemia clinical trials

Get alerts when Leukemia trials change

2,169 active trials 1,265 recruiting 192 Phase 3 690 sponsors 331 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 57 of 331 changes on 20 trials

2026-08-20
Trial terminated
Trial terminated: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug
Enrollment reduced: 10 → 4 participants
Primary completion moved earlier: 2028-12 → 2026-07-01
Completion moved earlier: 2028-12 → 2026-07-01
NCT07556757 A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… · ImmunityBio, Inc. · Phase 1
2026-08-28
Recruitment suspended
Recruitment suspended: Unacceptable Toxicity
NCT03816319 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… · National Cancer Institute (NCI) · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2028-07-31 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT04010877 Multiple CAR-T Cell Therapy Targeting AML · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-27
Withdrawn before enrolling
Trial withdrawn: Strategic adjustment.
Enrollment reduced: 10 → 0 participants
Primary completion moved earlier: 2028-10-31 → 2026-03-30
Completion moved earlier: 2028-10-31 → 2026-03-30
NCT07338357 Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · First Affiliated Hospital of Guangxi Medical University · Early Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2029-12-31 → 2026-07-01
Completion moved earlier: 2030-12-31 → 2026-07-31
NCT05277753 NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2029-12-31 → 2026-07-01
Completion moved earlier: 2030-12-31 → 2026-07-31
NCT05262673 NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-22
Recruitment suspended
Recruitment suspended: Accrual goal met
NCT03728335 Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation · City of Hope Medical Center · Phase 2
2026-08-21
Trial terminated
Trial terminated: \<75% participants
Primary completion moved earlier: 2026-11-30 → 2026-08-14
Completion moved earlier: 2026-11-30 → 2026-08-14
NCT02392572 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-14
Withdrawn before enrolling
Trial withdrawn: The trial has been stopped pending FDA approval of modifications to the trial protocol.
Enrollment reduced: 24 → 0 participants
NCT06703216 Pre-emptive Anakinra for Cytokine Event Reduction · Kevin McNerney · Phase 1/2
2026-08-07
Trial terminated
Trial terminated: The study was closed due to the end of funding.
NCT04994808 Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… · Fred Hutchinson Cancer Center · Phase 2
2026-08-11
Recruitment suspended
Recruitment suspended: Recruitment on hold with plans to open to accrual again soon.
NCT06492707 DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… · Fred Hutchinson Cancer Center · Phase 1
2026-09-04
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2027-12-31 → 2028-06-30
NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure… · Il-Yang Pharm. Co., Ltd. · Phase 3
2026-09-04
Primary completion pushed: 2026-05-31 → 2026-10-15
Completion pushed: 2026-08-31 → 2026-11
NCT04635384 Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT)… · CareDx
2026-09-04
Primary completion pushed: 2026-09-30 → 2027-07-15
Enrollment closed, study ongoing
Completion pushed: 2026-12-31 → 2027-12-31
NCT06665412 Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML · Il-Yang Pharm. Co., Ltd.
2026-09-05
Primary completion pushed: 2027-09 → 2028-03
Completion pushed: 2027-09 → 2028-03
NCT06262789 RAT-HEMATO : Return to Work After Malignant Hemopathy · University Hospital, Angers
2026-09-05
Primary completion pushed: 2025-06 → 2030-06-01
Completion pushed: 2030-04 → 2030-06-01
NCT01949129 Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute… · St. Anna Kinderkrebsforschung · Phase 2/3
2026-09-04
Primary completion pushed: 2028-12 → 2032-12
Primary endpoint(s) modified
Phase changed: Phase 1/2 → Phase 2/3
Interventions modified
Trial sites expanded: 19 → 31 locations
Completion pushed: 2028-12 → 2032-12
Trial arms changed: 18 → 23
NCT03013998 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia · Beat AML, LLC · Phase 2/3
2026-09-04
Primary completion pushed: 2026-09-30 → 2028-09-30
Completion pushed: 2026-09-30 → 2028-09-30
NCT02131584 Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia · M.D. Anderson Cancer Center · Phase 2
2026-08-21
Primary completion pushed: 2028-06-30 → 2028-12-31
Completion pushed: 2028-06-30 → 2028-12-31
NCT05579132 A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic… · MSD R&D (China) Co., Ltd. · Phase 1/2
2026-08-21
Primary completion pushed: 2027-09-16 → 2032-04-05
NCT02386800 CINC424A2X01B Rollover Protocol · Novartis Pharmaceuticals · Phase 4

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-04 NCT07804901 Asciminib Frontline Risk Adapted Prof. Dr. med. Andreas Hochhaus new Phase 2
2026-09-04 NCT07805096 Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and… National Defense Medical University, Taiwan new
2026-09-03 NCT07802015 Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish… Zealand University Hospital new
2026-08-31 NCT07795099 A Single-center, Prospective, Exploratory Clinical Study LanZhou University new
2026-08-19 NCT07774390 Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL European Research Initiative on CLL new
2026-08-19 NCT07773909 Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive… Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh new Phase 4
2026-08-18 NCT07771803 A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia… Roger Strair new Early Phase 1
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-12 NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. new Phase 1/2
2026-08-10 NCT07755202 Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With… Florian Kuchenbauer new Phase 2

Active trials by phase

Early Phase 1
70
Phase 1
447
Phase 1/2
259
Phase 2
607
Phase 2/3
46
Phase 3
146
Phase 4
20
Not charted: 574 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 2,169

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07218341 A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… Eli Lilly and Company Recruiting 2026-09-04
NCT06651970 Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL… AstraZeneca Recruiting 2026-08-14
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… AbbVie Recruiting 2026-08-14
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT06289673 Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute… St. Jude Children's Research Hospital Recruiting 2026-07-14
NCT04877522 Asciminib Roll-over Study Novartis Pharmaceuticals Recruiting 2026-07-06
NCT06370000 Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML)… Virginia Commonwealth University Recruiting 2026-05-29
NCT07561892 Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating… Fujian Medical University Union Hospital Recruiting 2026-05-01
NCT06876649 A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Eli Lilly and Company Recruiting 2026-03-02
NCT06876662 A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… Eli Lilly and Company Recruiting 2026-03-02
NCT07016165 Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in… Gadjah Mada University Recruiting 2025-08-22
NCT06918054 Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia Ain Shams University Recruiting 2025-04-09
NCT06571825 RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR He Huang Recruiting 2024-08-26
NCT06339775 Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation Suping ZHANG Recruiting 2024-04-01
NCT02386800 CINC424A2X01B Rollover Protocol Novartis Pharmaceuticals Active, Not Recruiting 2026-08-20
NCT07320534 Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During… Gadjah Mada University Not Yet Recruiting 2026-01-08
NCT03229200 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Pharmacyclics Switzerland GmbH Active, Not Recruiting 2025-10-30
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in… AbbVie Active, Not Recruiting 2025-08-12
NCT06918080 Hepatoprotective Measures for Children at High Risk of NAFLD Ain Shams University Active, Not Recruiting 2025-04-09
NCT04790045 Lymph Node Microenvironment Modifications in Patients With CLL Treated With… Paolo Ghia Not Yet Recruiting 2023-10-03
Phase 3
NCT04269902 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… National Cancer Institute (NCI) Recruiting 2026-09-04
NCT07022678 Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With… Children's Oncology Group Recruiting 2026-09-04
NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure… Il-Yang Pharm. Co., Ltd. Recruiting 2026-09-03
NCT03150693 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly… Alliance for Clinical Trials in Oncology Recruiting 2026-09-02
NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… Stichting Hemato-Oncologie voor Volwassenen Nederland Recruiting 2026-09-02
See all 2,169 active Leukemia trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (117) · National Cancer Institute (NCI) (89) · Institute of Hematology & Blood Diseases Hospital, China (65) · City of Hope Medical Center (58) · The First Affiliated Hospital of Soochow University (52) · Memorial Sloan Kettering Cancer Center (43) · Dana-Farber Cancer Institute (33) · Novartis Pharmaceuticals (25) · Peking University People's Hospital (25) · St. Jude Children's Research Hospital (25)

Get alerts when Leukemia trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free